BCAL Develops New Blood Test for Breast Cancer Recurrence
Filed with ASX · · 2 pages · English
Summary by 6ix AI
BCAL Diagnostics Limited has developed a new blood test called BREASTEST Monitor for evaluating local breast cancer recurrence after treatment. Preliminary findings indicate that the test has a high sensitivity and negative predictive value in identifying local recurrences. BCAL is seeking additional patients for further clinical validation studies before the commercial launch of the test.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- BCAL Launches Early Detection Cancer Platform
- BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
- BCAL Accelerates Rollout of Avantect Early Detection Tests
- Half Yearly Report and Accounts
- Shareholder Update
Later from BCAL Diagnostics
- BCAL Secures Funding for FY2027
- BCAL to Acquire Shares in Genetic Signatures
- BCAL Secures Funding for FY2027 Update
- BCAL Takes Interest in Genetic Signatures to 18.46%
- Appendix 4E and Annual Report to shareholders
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics